HUM trades 8.5% below Wall Street's consensus target of $470.42.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HUM achieves its forward estimates and maintains a stable P/E multiple of 47.4x. This scenario reflects the blended consensus of 44 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Humana Inc. (HUM) has a Wall Street consensus price target of $470.42, based on estimates from 44 covering analysts. With the stock currently trading at $433.74, this represents a potential upside of +8.5%. The company has a market capitalization of $52.08B.
Analyst price targets range from a low of $300.00 to a high of $596.00, representing a 63% spread in expectations. The median target of $475.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 20 analysts rating the stock as a Buy or Strong Buy,23 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, HUM trades at a trailing P/E of 44.1x and forward P/E of 47.4x. Analysts expect EPS to grow -13.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $842.03, with bear and bull scenarios of $530.48 and $1109.46 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 UNHUnitedHealth Group Incorporated | $357.9B | $394.15 | $478.68 | +21.4% | Buy | 19.1x | 52 |
 CVSCVS Health Corp. | $107.0B | $83.85 | $109.89 | +31.1% | Buy | 10.4x | 41 |
 ELVElevance Health Inc. | $92.3B | $425.62 | $466.69 | +9.6% | Buy | 14.7x | 38 |
 CNCCentene Corp. | $34.4B | $69.70 | $75.43 | +8.2% | Buy | 13.2x | 44 |
 MOHMolina Healthcare, Inc. | $10.9B | $208.99 | $216.73 | +3.7% | Buy | 39.7x | 39 |
 ALHCAlignment Healthcare, Inc. | $1.5B | $7.34 | $12.29 | +67.4% | Buy | — | 16 |
 OSCROscar Health, Inc. | $7.9B | $30.65 | $37.43 | +22.1% | Hold | 15.9x | 13 |
 CLOVClover Health Investments, Corp. | $2.5B | $4.82 | $5.63 | +16.8% | Hold | 88.0x | 9 |
 BHVNBiohaven Ltd. | $2.2B | $14.48 | $24.67 | +70.4% | Buy | — | 25 |
 ACGLArch Capital Group Ltd. | $37.5B | $107.28 | $112.50 | +4.9% | Hold | 10.6x | 34 |
Quick answers to the most common questions about buying HUM stock.
The consensus price target for HUM is $470.42, close to the current price of $433.74 (8.5% implied move). Based on 44 analyst estimates, the stock appears fairly valued near current levels.
HUM has a consensus rating of "Hold" based on 44 Wall Street analysts. The rating breakdown is mixed, with 23 Hold ratings making up the largest segment. The consensus 12-month price target of $470.42 implies 8.5% upside from current levels.
At a forward P/E of 47.3562x, HUM trades at a premium valuation. The consensus price target of $470.42 (8.5% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $596 for HUM, while the most conservative target is $300. The consensus of $470.42 represents the median expectation. Our quantitative valuation model projects a bull case target of $1109 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HUM is heavily covered by Wall Street, with 44 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 23 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HUM stock forecast based on 44 Wall Street analysts shows a consensus price target of $470.42, with estimates ranging from $300 (bear case) to $596 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $842, with bear/bull scenarios of $530/$1109.
Our quantitative valuation model calculates HUM's fair value at $842 (base case), with a bear case of $530 and bull case of $1109. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
HUM trades at a forward P/E ratio of 47.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 44.1x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
HUM appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $470.42 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HUM analyst price targets range from $300 to $596, a 63% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $470.42 consensus represents the middle ground. Our model's $530-$1109 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.